FDA Approved: IBUPROFEN — Supplemental Application (Chartwell RX, LLC)

View source ↗

Summary

The FDA approved a supplemental application for ibuprofen from Chartwell RX, LLC under ANDA 202413, authorizing the specified changes to this generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysmenorrhea
• Headache
• Migraine
• Osteoarthritis
• Rheumatoid Arthritis

Drugs mentioned

• Ibuprofen (IBUPROFEN)

Snippet

SUPPL AP for IBUPROFEN (IBUPROFEN)